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Abstract
Blood pressure increases with age, and dysfunction of the dopamine D3 receptor has been implicated in the pathogenesis
of hypertension. To evaluate the role of the D3 receptor in aging-related hypertension, we assessed cardiac structure and
function in differently aged (2 mo, 1 yr, 2 yr) wild type (WT) and young (2 mo) D3 receptor knockout mice (D3KO). In WT,
systolic and diastolic blood pressures and rate-pressure product (RPP) significantly increased with age, while heart rate
significantly decreased. Blood pressure values, heart rate and RPP of young D3KO were significantly elevated over age-
matched WT, but similar to those of the 2 yr old WT. Echocardiography revealed that the functional measurements of
ejection fraction and fractional shortening decreased significantly with age in WT and that they were significantly smaller in
D3KO compared to young WT. Despite this functional change however, cardiac morphology remained similar between the
age-matched WT and D3KO. Additional morphometric analyses confirmed an aging-related increase in left ventricle (LV) and
myocyte cross-sectional areas in WT, but found no difference between age-matched young WT and D3KO. In contrast,
interstitial fibrosis, which increased with age in WT, was significantly elevated in the D3KO over age-matched WT, and
similar to 2 yr old WT. Western analyses of myocardial homogenates revealed significantly increased levels of pro- and
mature collagen type I in young D3KO. Column zymography revealed that activities of myocardial MMP-2 and MMP-9
increased with age in WTs, but in D3KO, only MMP-9 activity was significantly increased over age-matched WTs. Our data
provide evidence that the dopamine D3 receptor has a critical role in the emergence of aging-related cardiac fibrosis,
remodeling, and dysfunction.
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Introduction
Normal aging is a complex composite of several different
processes that can be distinguished from age-related diseases, and
it is associated in humans with a gradually increasing risk of
cardiovascular disease [1,2] including hypertension [3,4]. While
the cardiovascular autonomic changes related to aging are well
described both functionally [5] and morphologically [6], emerging
data suggest that cardiac aging is also associated with ventricular
hypertrophy and fibrosis [7], caused by reduced matrix proteo-
loysis and progressive deposition of collagen in the interstitial space
[7,8].
A role for the neuromodulator dopamine (DA) in the
pathophysiology of hypertension has been well established
[9,10]. DA acts through two different receptor subfamilies, D1-
like (D1, D5) and D2-like (D2, D3, D4), and DA usually has lower
affinity for D1-like versus D2-like receptors. There is evidence for
a role of both D1 [11,12] and D3 receptor-mediated effects in the
pathophysiology of hypertension [13,14,15,16]. The D3 receptor
is expressed in the heart [17], and several mechanisms have been
reported by which failure of the D3 signaling system in the
periphery might account for an increase in blood pressure
[16,18,19]. These include interaction with the D1 receptor
subtype [20], angiotensin II [21], endothelin binding receptors
[22], or the G protein-coupled receptor kinase 4 in the kidney or
Na+ transporters in the renal tube [23,24].
Based on the established association between aging and the
development of hypertension and considering observations that
the D3 receptor knockout mouse (D3KO) expresses a hypertensive
phenotype [16], we hypothesized that a dysfunction of the D3
receptor signaling pathway is associated with the cardiac fibrosis
and dysfunction observed with normal aging and that it can mimic
age-dependent changes of the cardiovascular system in these
animals. Using non-invasive in vivo blood pressure measurements,
functional echocardiography, in vitro histology and expression and
activity assays on hearts of differently-aged WT (2 mo, 1 yr, 2 yr)
and young (2 mo) D3KO mice, we found that aging-related
changes in blood pressure and cardiac fibrosis in WT are largely
mimicked in young D3KOs. Intriguingly, these blood pressure and
echocardiography data resemble aging-related changes observed
in healthy, senescent humans. We propose that in aged WT and
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young D3KO mice, these changes occur through a collagen type
I/matrix metalloproteinase-9 (MMP-9)-mediated mechanism.
Based on these novel findings, we introduce the idea that the
dopamine D3 receptor serves as a regulator for aging-related
cardiac fibrosis and dysfunction. Thus D3KOs may provide a new
experimental model with which to understand the role of DA/D3
receptor signaling in the aging heart.
Materials and Methods
Animals and housing
All experimental procedures were approved by the East
Carolina University Animal Care and Use Committee according
to the National Institutes of Health Guide for the Care and Use of
Laboratory Animals (US NIH, Pub. No. 85-23, rev. 1996), and all
efforts were made to minimize animal suffering. Experimental
animals were divided into three age groups: wild type (WT) mice
(C57BL/6): 2 mo (n= 10), 1 yr (n = 12), and 2 yr (n = 10). D3KO
mice on a C57BL/6 background (B6.129S4-Drd3tm1Dac/J, n= 10)
were obtained from Jackson Laboratory, Bar Harbor, ME, and
maintained as a breeding colony at ECU. Animals were kept
under identical conditions in the Brody School of Medicine
Animal Facility with a 12:12 h light-dark cycle and free access to
standard mouse chow and water. Two additional cohorts of
animals were used to assess potential differences in mortality
between the two strains (WT: n= 14; D3KO: n= 15).
Blood pressure measurements
Systolic and diastolic blood pressures and heart rates were
measured in conscious mice using a non-invasive tail cuff
measurement system (Model SC1000 Blood Pressure Analysis
System, Hatteras Instruments, Cary, NC). Animals were placed on
a warming platform (37–38uC), and a magnetic metal holder was
used to restrict movement. A tail-cuff occluder was placed
proximally on the tail, which was then immobilized with tape in
a V-shaped block between a light source above and a photoresistor
below with a LED assembly to detect the pulse. Data were
displayed, recorded (SC1000 Comm Windows, version 2.50) and
exported to SigmaPlot (v. 11; Systat Software, Inc., Chicago, IL)
for analysis. The minimum pulse amplitude was set to 20%, the
systolic threshold to 5%, and the maximum pressure to occlude
blood flow in the tail to 200 mmHg.
Recording sessions usually lasted less than 10 minutes to
complete per animal and consisted of 5 acclimatization cycles and
10 measurement cycles for systolic and diastolic blood pressure
and heart rate. Measurements were performed at similar times of
day to maintain consistency and to avoid circadian perturbations.
Only animals of the same age group or strain were measured on a
given day, and recording sessions were repeated daily, typically for
4–5 days.
Functional echocardiography
Animals underwent high-resolution echocardiography (Vevo
2100, VisualSonics, Toronto, ON) using a 30 MHz transducer. All
behavioral experiments were performed at room temperature.
Following protocols described elsewhere [25], animals were
anesthetized (2% isoflurane) and placed on a platform under a
fume hood where the anesthesia was maintained via a nose cone.
The chests were depilated (NairH) to minimize ultrasound
attenuation, and a contact gel (Aquasonic, Parker Laboratories,
Fairfield, NJ) was applied to the thorax surface to optimize
visibility of the heart. Parasternal long- and short-axis views were
acquired in M-mode, and the system software then measured or
calculated off-line the following parameters: systolic and diastolic
diameters, ejection fraction, fractional shortening, left ventricle
(LV) mass, LV mass/body weight, systolic and diastolic volume,
stroke volume, cardiac output, and heart rate. While the functional
echocardiography cannot measure cardiac chamber pressures and
volumes, this non-invasive approach permitted us to obtain
repeated datasets from the animals without fear of jeopardizing
the measurements of these baseline parameters by additional
cardiac catheterization.
Tissue harvesting and histology
After in vivo data were acquired, animals were deeply
anesthetized by exposure to isoflurane and decapitated. Hearts
were quickly harvested and either snap-frozen in liquid nitrogen
(n= 5 per group and strain, LV only) for protein analyses or fixed
in zinc-based fixative (n = 5 per group and strain, whole heart),
processed, and embedded according to routine procedures for
histological analyses [26].
For morphometric analyses of left ventricle (LV) area, chamber
area, and myocyte cross-sectional area (MCSA), slides were
stained with hematoxylin and eosin. Briefly, for ventricular and
chamber areas, 4 sections per heart were imaged at 206, the
measurements were averaged per animal, and each of those
averages was used to calculate the mean and variation for all
hearts in each group. For MCSA, 3 images in both the epicardial
and endocardial regions of 2 sections per hearts were taken. In
each image, the area of 3–8 myocytes with centrally located nuclei
was measured and recorded. The average of these numbers were
calculated for each animal and then those numbers were averaged
for n = 5 per group [27].
Fibrosis staining
Picrosirius Red/Fast Green staining protocol was performed
according to routine procedures in order to quantify interstitial
collagen content in the LV [28]. Briefly, slides were de-
paraffinized and rehydrated, immersed in a 0.1% picrosirius
red/fast green solution (Sigma-Aldrich, 365548, F7258, P6744) for
30 min, cleared and coverslipped [29]. Using Adobe Photoshop
software (Adobe Systems, Mountain View, CA), red collagen fibril
pixels were then counted and expressed as a percentage of the total
number of pixels (total = green + red 2 white).
Immunoprecipitation
Mouse WT and D3KO whole heart lysates were diluted to
1 mg/ul total protein (in PBS) and pre-cleared with protein A-
agarose/sepharose beads (50%, v/v in PBS). Beads were removed
and the supernatants were incubated in immunoprecipitating
antibody overnight at 4uC, after which the immunocomplex was
captured with protein A beads. Protein A-antigen complexes were
pelleted by centrifugation at 14,000 rpm for 5 seconds. Pellets
were washed 36 in ice cold PBS, the beads resuspended, boiled
(5 min), centrifuged (5–7 minutes), and the immunocomplexes
were resolved by SDS-PAGE followed by Western blotting for
collagen types I, III, and IV.
Western blotting
Western blotting was performed as routine for collagen types I,
III, and IV [30,31]. Briefly, prepared immunocomplexes were
transferred to nitrocellulose membrane, blocked and incubated
with antibodies directed against collagen types I and IV (1:500
each, Santa Cruz) and type III (1:1000; Abcam) overnight at 4uC.
After washes the membranes were incubated in anti-rabbit
horseradish peroxidase-conjugated secondary antibodies (1:1000)
for 1 hr at room temperature. Blots were washed and incubated in
Dopamine D3 Receptor and Aging Heart Function
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Pierce enhanced chemoluminescence reagents (Thermo Scientific)
and exposed to photographic film. Densitometry was performed
using ImageJ software (version 1.45 s, National Institutes of
Health). Blots were stripped of primary antibodies at 50uC for 30
minutes using a stripping solution containing 10% SDS and
100 mM 2-mercaptoethanol in 62.5 mM Tris buffer (pH 6.8), and
re-probed for a-tubulin. Data are represented as collagen
expression normalized to alpha-tubulin within each sample.
Column zymography
Column gel zymography was performed as previously described
[32,33] to assess gelatinolytic activities of MMP-2 and MMP-9.
Secreted MMP activities from whole heart homogenates were
assessed using Novex 10% Tris-glycine zymogram gels containing
0.1% gelatin and using XCell SureLock Mini-Cells (Invitrogen).
Briefly, samples were denatured in SDS buffer under non-
reducing conditions and then electrophoresed in the presence of
SDS running buffer. Samples were renatured, equilibrated,
destained, and regions of MMP activity were quantified with
ImageJ.
Animal survival
In order to determine survival of WT and D3KO mice, a
Kaplan-Meier analysis was performed using terminal morbidity or
mortality as the endpoint. An additional 14 male WT and 15 male
D3KO mice were used for these studies.
Statistical analysis
All data are presented as mean 6 standard error of the mean
(SEM). SigmaPlot 11 (Systat Software, Inc., Chicago, IL) was used
to analyze data and to test for significant differences in the course
of an experiment. Unless otherwise stated, a One-way Analysis of
Variance (ANOVA) was performed on data at a minimum
p,0.05 threshold, and appropriate post-hoc tests were applied to
evaluate differences between treatment groups.
Results
Blood pressure & heart rate measurements
Non-invasive blood pressure and heart rate recordings were
obtained from a total of 36 animals: 2 mo WT (n= 10), 1 yr WT
(n= 12), 2 yr WT (n= 8), and 2 mo D3KO (n= 6). On average,
animals in each group were subjected to 4–5 recording sessions,
with the first 2–3 sessions used to acclimate the animals and the
last 3 sessions used for data analysis.
In WT animals, aging was accompanied by significant increases
in systolic and diastolic blood pressures (Figs. 1A, 1B, respectively).
Systolic values were similar between the 2 mo and 1 yr old WT
animals (94.1761.94 mmHg and 96.5761.95 mmHg, respective-
ly), but increased significantly by year 2 to 143.7663.57 mmHg
(p,0.001, Fig. 1A). In comparison, diastolic values showed a
significant, age-dependent increase from 42.0960.65 mmHg at 2
months to 56.5961.67 at 1 year to 83.9763.3 at 2 years of age in
the WT mice (p,0.001, Fig. 1B). Intriguingly, systolic blood
pressure in the young 2 mo old D3KO (141.8562.72 mmHg) was
comparable to that of the 2 yr old WT mice and was significantly
higher than for the 2 mo old WT (Fig. 1A). Similarly, diastolic
blood pressures of the young 2 mo old D3KO (69.7161.1 mmHg)
were comparable to those of the 2 yr old WTs and were
significantly higher than the age-matched WT (Fig. 1B, p,0.001).
Increases in blood pressures with age in WT mice were
paralleled by a corresponding significant increase in mean arterial
pressure (MAP) from 59.460.9 mmHg at 2 mo over
69.961.7 mmHg at 1 yr, to 103.9.8562.6 mmHg at 2 yr
(Fig. 1C, p,0.001, ANOVA). MAPs of the young D3KO animals
were slightly, albeit significantly, lower than those of the 2 yr old
WT (93.861.6 mmHg), but still significantly higher than of both
2 mo and 1 yr old WTs (p,0.001, ANOVA).
Increases in blood pressures and MAP with age in the WT mice
were accompanied by a strong decrease in heart rate from
714.8866.96 beats-per-minute (bpm) at 2 mo to 660.8569.3 bpm
at 2 yr (Fig. 1D). This bradycardia in the 2 yr old WT animals was
mimicked in the young 2 mo D3KOs (632615.32 bpm, p,0.001,
Fig. 1D). To assess myocardial oxygen requirements and work
load, rate pressure product (RPP) was calculated as a product of
systolic blood pressure x heart rate (Fig. 1E). The RPP in WT mice
rose from 6730261430 at 2 mo over 7093661151 at 1 yr to
9497462530 at 2 yrs (+41%; p,0.001). The RPP in 2 mo old
D3KO was comparable to that of the 2 yr old WT but was
significantly increased (33%; p,0.001) over age-matched WT
controls (8956562176; Fig. 1E). Together, these data provide
evidence that the aging-related changes in blood pressure and
heart rate affiliated with old WT are already present in young
D3KO mice.
Table 1 lists body weights for the four animal cohorts in our
study. In WT, we observed a significant increase in body weight
with age with a peak at a 1 year (p,0.033, ANOVA); however, we
did not detect differences between 2 mo old WT and age-matched
D3KOs. This suggests that the observed differences in blood
pressure, heart rate, RPP, and MAP between the age-matched
WT and D3KO did not arise from differences associated with
body weight.
Functional echocardiography
To determine if aging-related changes in blood pressure and
heart rate were related to alterations in cardiac function, we next
performed ultrasound echocardiograms in anesthetized animals.
Cardiac echograms were analyzed from 2 mo (n= 9), 1 yr (n = 7),
and 2 yr old WTs (n = 6), and 2 mo old D3KOs (n= 5), and data
are reported in Figures 2 and 3. Overall, six morphological
(Figure 2) and four functional parameters (Figure 3) were
measured or calculated and compared between all groups.
Systolic diameter (Fig. 2A1) gradually increased with age in WT
from 2.260.2 mm at 2 mo to 2.960.2 mm at 2 yr (p = 0.029),
however we did not find any difference between 2 mo old D3KO
(2.3660.06 mm) and age-matched WT. Measurements for systolic
volume (Fig. 2B1) displayed a similar trend: from 18.663.5 ml in
2 mo WT to 32.463.1 ml in 2 yr old WT (p= 0.024), while systolic
volume in the 2 mo old D3KO (20.260.9 ml) remained similar to
the age-matched WT.
Diastolic diameters (Fig. 2A2) only slightly and insignificantly
increased with age in WT, from 3.560.17 mm at 2 mo to over
4.0560.21 mm at 1 yr to 3.9560.2 mm at 2 yr. Diastolic
diameters of 2 mo D3KO were again similar to their age-matched
WT controls (3.3 mm60.1 mm), which were significantly smaller
than the 1 yr WT (p= 0.037, Fig. 2A2). Similar to the trends
observed between systolic diameter and volume, diastolic volume
displayed a trend towards an increase in aging WT (2 mo:
44.2866.2 ml; 1 yr: 89.6 ml68.5 ml; 2 yr: 58.868.8 ml), but was
similar between age-matched WT and D3KO (D3KO:
44.563.53 ml). However, the difference between 1 yr old WT
and 2 mo D3KO was significant (p = 0.04, Fig. 2B2).
With age, LV mass increased in WT, from 94.764.6 mg at
2 mo to 132.167.9 mg at 2 yr (Fig. 2C1). LV mass was similar, if
slightly reduced, in 2 mo D3KO compared to age-matched WT
controls (74.564.4 mg), and was significantly lower than those of
1- and 2 yr WT (p= 0.001).
Dopamine D3 Receptor and Aging Heart Function
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To account for the increase in body weight of the WT animals
with age, we adjusted LV mass to body weight (Fig. 2C2). We
found that in WT the LV mass/body weight ratio remained stable
with age (2 mo: 0.3560.02%; 1 yr: 0.3360.03%; 2 yr:
0.3860.02%), but was significant decreased in the young D3KO
compared to age-matched and 2 yr old WTs (p = 0.001). These
Figure 1. Blood pressure, heart rate, and rate-pressure product in WT and D3KO. A. Systolic blood pressure is stable in WT from 2 mo to
1 yr, but significantly increases from 1 yr to 2 yr (p,0.001, ANOVA). D3KO show similar values to 2 yr old WT. B. Diastolic blood pressure increases
gradually with age in WT and reaches its peak at 2 years of age. D3KO show levels comparable to those of the 2 yr old WT and significantly higher
than 2 mo or 1 yr old WT (p,0.001, ANOVA). C. Mean arterial pressure (MAP) increases gradually with age in WT and reaches its peak at 2 years of
age. D3KO show levels comparable to those of the 2 yr old WT and significantly higher than 2 mo or 1 yr old WT (p,0.001, ANOVA). D. Heart rate
reaches a peak in 1 yr old WT and drops significantly in the 2 yr old WT, and values are similar between 2 yr old WT and 2 mo old D3KO. E. The rate-
pressure product increases with age in WT and is similar between 2 yr old WT and 2 mo old D3KO.
doi:10.1371/journal.pone.0074116.g001
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findings suggest that the hypertension observed in young D3KO is
not associated with anatomical changes in the hearts of these
animals or with cardiac muscle hypertrophy. We therefore next
assessed the functional parameters of cardiac function in WT and
D3KO.
In WT mice, ejection fraction (Figure 3A) significantly
decreased with age from 2 mo (6863.2%) over 1 yr
(61.761.6%) to 2 yrs (52.863.9%; p= 0.01). In D3KO, ejection
fraction (5464.3%) was significantly smaller than in age-matched
WT (p= 0.01) but similar to that of the 2 yr WT cohort. Fractional
shortening (Figure 3B) displayed a similar trend, with values
significantly decreasing with age in WTs from 37.862.5% at 2 mo
to 27.162.5% at 2 yr (p = 0.012). Again, values for 2 mo D3KOs
mimicked those of old WT and were significantly decreased from
age-matched WTs (28.262.9%, p= 0.012).
Unlike ejection fraction and fractional shortening, stroke
volume did not change significantly with age in WT mice
(Figure 3C). We observed a slight increase from 2 mo to 1 yr, but
no significant differences between young and old WT (2 mo:
34.462.7 ml; 1 yr: 4564.7 ml; 2 yr: 37.467.1 ml). In contrast,
stroke volume in the young D3KO (24.763.7 ml) showed a strong
trend (p = 0.054) for a decrease over age-matched WT. Assessing
Table 1. Animal weights.
2 mo WT 1 yr WT 2 yrs WT 2 mo D3KO ANOVA
Body weight (g) 26.8361.48 42.4966.98¡ 35.1563.57 28.9861.99 p = 0.033
Average values 6S.E.
¡ = significant difference between 2 mo WT and 1 yr WT.
doi:10.1371/journal.pone.0074116.t001
Figure 2. Changes in heart morphology with age. A1. In WT, systolic diameter increases with age and is significantly larger in 2 yr old WT
compared to 2 mo. Systolic diameter in D3KO is not significantly different from age-matched WT. A2. In WT, diastolic diameter slightly increases with
age and is significantly larger in 1 yr old WT compared to 2 mo old D3KO. Diastolic diameter in D3KO is not significantly different from age-matched
WT. B1. In WT, systolic volume increases with age and is significantly larger in the 2 yr WT compared to the 2 mo old WT, but systolic volumes of age-
matched WT and D3KO are similar. B2. In WT, diastolic volume increases with age and is significantly larger in 1 yr old WT over 2 mo, but diastolic
volumes of young WT and D3KO are similar. C1. Left ventricle (LV) mass increases with age in WT and is significantly larger in 1 and 2 yr old WT
compared to 2 mo old WT; however, LV masses between age-matched WT and D3KO are not significantly different. C2. In WT, LV mass adjusted for
body weight remains stable with age but is significantly decreased in 2 mo old D3KO compared to 2 yr and 2 mo old WT.
doi:10.1371/journal.pone.0074116.g002
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cardiac output (Figure 3D), we observed in WT a significant
increase from 2 mo (12.560.9 ml/min) to 1 yr (21.162.1 ml/in,
p,0.001), followed by decrease at 2 yr (15.362.8 ml/min).
Cardiac output of D3KO (8.861.4 ml/min) was significantly
lower than that of the 2 mo WT (p= 0.04, t-test). These data
suggest that cardiac dynamic function appears to be compromised
in young D3KO compared to age-matched WT controls. The
numerical data from figures 3 and 4 are summarized in Table 2.
Morphometric analyses
We next assessed the morphometric features of the WT and
D3KO hearts and measured LV total area and chamber area and
MCSAs of both the endo- and epicardium (see Table 3). We found
aging-related increases in WT for LV total area and LV chamber
area, but no significant differences between age-matched WT and
D3KO. Both LV total area and chamber areas were significantly
smaller in D3KO than in 2 yr WT (p= 0.009 and p= 0.007,
respectively. Similarly, in WT, MCSA of both endo- and
epicardial areas increased significantly from 2 mo to 1 yr of age,
and the 1 yr WT animals were significantly different from 2 mo
D3KO (p,0.001), but we did not detect any differences between
age-matched WT and D3KO. These data suggest that the
increase in blood pressure and the reduction in heart rate and
cardiac function observed in D3KO are not caused by changes in
MCSA and LV size.
Histological analyses
As cardiac fibrosis is a hallmark of heart disease and
hypertension [7,34], we next assessed fibrosis and fibrotic
collagen in the heart (Figure 4). In 2 mo WTs, we detected low
levels of interstitial fibrosis (Figure 4A, arrow), and with
increasing age, fibrosis-positive labeling strongly increased
(Figure 4B, C, arrows). Surprisingly, in 2 mo D3KO hearts,
fibrosis labeling was stronger than in age-matched WTs and was
comparable to the labeling observed in the 2 yr WT (Figure 4D,
arrows). Quantification of the histological data (Figure 5) revealed
significant increases in total myocardial fibrosis with age in the
WT animals (by, at 1 yr: 9.567.3%; 2 yr: 24.866.1% versus
Figure 3. Changes in heart function with age. A. In WT, ejection fraction decreases with age and is significantly reduced in 2 yr old WT
compared to 2 mo. Ejection fraction in D3KO is significantly reduced from age-matched WT and is comparable to that of the 2 yr old WT. B. In WT,
fractional shortening decreases with age and is significantly reduced in the 2 yr old WT versus 2 mo old WT. Note that D3KO fractional shortening is
significantly reduced from age-matched WT but similar to that of the 2 yr old WT. C. Stroke volume peaks in WT at 1 yr before returning at 2 yrs to
similar values as in 2 mo old WT. In D3KO stroke volume is significantly decreased over age-matched WT controls. D. Similar to stroke volume, cardiac
output in WT significantly increases from 2 mo to 1 year before declining at 2 yrs of age. In D3KO cardiac output is significantly reduced compared to
1 yr old WT (p,0.001, ANOVA), or when solely compared to age-matched WT controls (p = 0.04, t-test).
doi:10.1371/journal.pone.0074116.g003
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Figure 4. Myocyte interstitial fibrosis with age. Representative images of the left ventricle myocardium of 2 mo old WT (A), 1 yr old WT (B), 2 yr
old WT (C), and 2 mo old D3KO mice (D). Images show increased content and thickness of fibrillar collagen with age (arrows) in WT hearts and in
young D3KO hearts.
doi:10.1371/journal.pone.0074116.g004
Table 2. Echocardiogram analysis.
2 mo WT 1 yr WT 2 yrs WT 2 mo D3KO
Systolic diameter (mm) 2.2260.56 2.7360.45 ¡ 2.8360.26 1 2.2160.25 i
Diastolic diameter (mm) 3.5160.52 4.0560.57 3.960.38 3.2660.25 i
Ejection fraction (%) 6863.2 61.6561.6 53.1863.9 1 5562.9 J
Fractional shortening (%) 37.7662.5 32.8461 27.3962.6 1 2862.9 J
LV mass (mg) 94.66613.88 138.52632.56 ¡ 133.64617.38 1 72.29610.67 i,*
LV mass/body weight (%) 0.3560.05 0.3360.08 0.3860.05 0.2560.04 J, i,*
Systolic volume (ml) 18.6610.57 29.21610.71 ¡ 31.1166.57 1 18.0563.05*
Diastolic volume (ml) 52.99618.5 74.28622.62 ¡ 67.17615.85 43.8168.31 i,*
Stroke volume (ml) 34.3968.2 45.07612.41 36.06614.31 25.7667.96 i
Cardiac output (ml/min) 12.5562.8 21.1465.52 ¡ 14.5965.23 9.3263.14 i,*
Average values 6S.E.
¡ = significant difference between 2 mo WT and 1 yr WT.
1= significant difference between 2 mo WT and 2 yrs WT.
J = significant difference between 2 mo WT and 2 mo D3KO.
i = significant difference between 1 yr WT and 2 mo D3KO.
* = significant difference between 2 yr WT and 2 mo D3KO.
doi:10.1371/journal.pone.0074116.t002
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2 mo WT; p= 0.002). Importantly, cardiac fibrosis expression in
2 mo D3KO was also significantly increased over age-matched
WTs (by 34.868.5%, p= 0.002, Figure 5). These data suggest
that increased interstitial fibrosis may play a critical role in the
emergence of hypertension and bradycardia in the young
D3KOs.
Western blot and zymographic analyses
Interstitial fibrosis partly arises from an increased deposition of
collagen in the extracellular space [7], and of the six collagen types
found in the heart, collagen type-I, type-III, and type-IV are most
commonly associated with fibrosis [34,35,36]. As a wide range of
mechanisms have been associated with cardiac fibrosis (e.g.
reactive oxygen species, angiotensin or endothelin signaling
pathways, growth factor activation), we focused here on the link
between collagen and matrix-metalloproteases (MMPs), using
immunoprecipitation and Western blotting approaches. We found
significant increases of both pro- and mature collagen type I with
age in WT hearts (p = 0.002 and p= 0.005, respectively,
Figure 6A). Furthermore, levels of both pro- and mature collagen
type-I in the 2 mo D3KO were similar to 2 yr WT and
significantly increased over age-matched WT (p= 0.002,
Figure 6A). In comparison, expression of collagen type-III
(Figure 6B) or type-IV (Figure 6C) did not change significantly
with age in WT hearts, nor were they significantly modified in the
2 mo D3KO compared to their age-matched WT controls.
To test whether the increased expression of collagen type I was
affiliated with parallel changes in matrix metalloproteinase (MMP)
activity, we assessed myocardial activity of MMP-2 [37] and
MMP-9 [38] (Figure 7). In WT hearts, MMP-2 activity showed a
strong trend to increase with age, but activity levels of 2 mo WT
and 2 mo D3KO were comparable. Similarly, MMP-9 activity
increased with age in WT, but MMP-9 levels were significantly
higher in D3KO compared to all WT cohorts (p = 0.022,
Figure 7B). Together, these data suggest that the aging-related
changes in hypertension and bradycardia observed in old WT are
already present in young D3KO, and they indicate that these
changes with age and in D3KO may be related to an increased
interstitial fibrosis in the heart, possibly mediated by collagen type-
I and MMP-9 pathways.
Animal survival
As our previous data suggested that a dysfunction of the D3
receptor is associated in young D3KO with an increase in blood
pressure and cardiac fibrosis observed otherwise only in aged WT
animals, we wanted to assess the physiological importance of D3
receptor function on life span. As shown in Figure 8, a Kaplan-
Meier survival analysis indicates a reduced life span for the D3KO
animals. Specifically, D3KO mice started prematurely dying at
about 7 months of age, either due to terminal morbidity or
mortality, and at 16 months of age only 67% D3KO mice had
survived (10 out of 15 animals). In contrast, all 14 WT were still
alive by this time. These data strongly suggest that a systemwide
dysfunction of the D3 receptor not only affects cardiac function,
but also severely shortens life span.
Discussion
We present here compelling evidence that a dysfunction of the
dopamine D3 receptor is associated with hypertension and
myocardial interstitial fibrosis and that these consequences mimic
aging-related alterations in cardiac remodeling and function,
possibly impacting life span.
Using non-invasive blood pressure measurements and function-
al echocardiography, together with morphometric analyses,
histology, protein expression and activity assays in vitro, we found
that aging-related changes of cardiac function and remodeling
observed in aged (2 yr old) WT are largely mimicked in young
(2 mo old) D3KO animals.
Table 3. Morphometric analysis.
2 mo WT 1 yr WT 2 yrs WT 2 mo D3KO ANOVA
LV area (mm2) 15.7961.62 20.3860.87 20.261.3 15.0260.76 i,* P= 0.009
LV chamber area (mm2) 2.116 0.05 2.2460.22 2.5860.21 1.5160.09* p= 0.007
MCSA epicardium (mm2) 230.2613.58 323.96 616.54 ¡ 267.8 612.67 230.93 613.52 i p,0.001
MCSA endocardium (mm2) 284.3613.98 340.93612.57 ¡ 254.7269.66 265.3768.26 i p,0.001
Average values 6S.E.
¡ = significant difference between 2 mo WT and 1 yr WT.
"= significant difference between 1 yr WT and 2 yrs WT.
i = significant difference between 1 yr WT and 2 mo D3KO.
* = significant difference between 2 yr WT and 2 mo D3KO.
doi:10.1371/journal.pone.0074116.t003
Figure 5. Quantification of myocyte interstitial fibrosis with
age. Levels of fibrosis gradually rise with age in the WT hearts and are
significantly increased in the 2 yr old WT hearts compared to the 2 mo
old WT. Fibrosis is also significantly increased in 2 mo old D3KO hearts
over age-matched WT and similar to levels observed in the 2 yr old WT.
doi:10.1371/journal.pone.0074116.g005
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Specifically, systolic and diastolic blood pressures and heart
rates in 2 mo old D3KO were significantly increased over age-
matched WT controls but similar to those of the 2 yr old WT
group. Echocardiography failed to reveal morphological differ-
ences between age-matched young WT and D3KO, but did
demonstrate a decline of function in fractional shortening and
ejection fraction in young D3KO that mimicked those of old WT
animals. Subsequent histological analyses revealed an aging-
related increase in interstitial fibrosis in the myocardium of WT,
with fibrosis in the 2 yr WT equivalent to that observed in the
2 mo D3KO. Western blot analyses suggest that this aging-related
fibrosis in WT might be due to increased expression of collagen
type I, which was also significantly elevated in the D3KO over its
age-matched control. Lastly, activities of MMP-2 and MMP-9
increased with age in WT; however, only MMP-9 activity both
increased in WT with age and was similar in D3KO to that in 2 yr
old WT. Together, these comprehensive findings attest that the
dopamine D3 receptor is critical in maintaining cardiac health and
homeostasis, and in turn that the dysfunction of the D3 receptor
results in exaggeration of an aging phenotype in the heart that
appears to be related to the collagen type-I/MMP-9 signaling
cascade.
An elevation in blood pressure in aging humans has been well
documented; however, the underlying causes for the development
of hypertension with age remain uncertain. Proposed mechanisms
center around pathologic renal defects, such as alterations in the
renin/angiotensin system [39,40], SNS dysfunction [41], or
abnormalities during cardiovascular development. All of these
etiologies potentially contribute to the development of hyperten-
sion with age [42].
During the early pathogenesis of hypertension, an increase in
cardiac output subsequently leads to increased vascular resistance,
Figure 6. Quantification of Western blot analyses for collagen types-I, type-III, and type-IV, normalized to a-tubulin. A. Collagen-type
I: expression levels of immature (pro) and mature forms of collagen type-I increase significantly with age in WT hearts and are similar between 2 yr
old WT and 2 mo old D3KO. B. Collagen type-III: expression levels of collagen type III were similar in young and old WT hearts and were not
significantly different in D3KO. C. Collagen type-IV: as with collagen type-III, expression levels of collagen type-IV were similar in the hearts of young
and old WT and D3KO.
doi:10.1371/journal.pone.0074116.g006
Figure 7. Quantification of matrix metalloproteinase activities. A. MMP-2: In WT, MMP-2 activity increased with age and was similar between
age-matched WT and D3KO. B. MMP-9: as with MMP-2, MMP-9 activity increased with age in WT, but was significantly higher in young D3KO
compared to WT hearts at any age (ANOVA).
doi:10.1371/journal.pone.0074116.g007
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and these events appear to be primarily neurogenic in origin
[41,43,44]. In contrast, in long-term hypertensive patients, blood
volume and cardiac output generally return to normal levels, but
vascular resistance remains elevated possibly through structural,
non-neurogenic mechanisms. This division between the stages of
hypertension is important in determining the underlying mecha-
nisms, and our findings point to a role for the D3 receptor in the
emergence of hypertension in its chronic form.
Dopamine is a potent neurotransmitter that also markedly
contributes to the control of cardiac and vascular function,
including heart rate variability (HRV), which is considered a
measure of autonomic regulation of cardiac activity [45,46]. We
recently reported that treatment with a D3 receptor agonist
improved HRV in patients with Restless Legs Syndrome (RLS)
[47], suggesting that activation of this inhibitory dopamine
receptor can boost both neurological and autonomic functions.
While our tail-cuff method to measure blood pressure and heart
rate did not provide a sufficiently-fast time resolution to directly
measure HRV, and while we abstained in this study from
interventional approaches to directly measure HRV or cardiac
pressures and volumes, our survival data suggest that a dysfunction
of the D3 receptor is affiliated with a risk for a decreased life span.
The D3KO mouse, originally characterized phenotypically as
hyperactive with elevated locomotor activity, reduced anxiety, and
hypertension [16,48], has been previously proposed as a model for
RLS [49]. Interestingly, patients suffering from RLS often present
clinically with high blood pressure and cardiovascular disease
[50,51]. Moreover, the severity of RLS pathology and symptom-
atology worsen with age, and treatment with D3-receptor agonists
can remediate RLS symptoms including hypertension [52,53].
These findings establish a basis for our theory that the D3 receptor
system plays a pivotal role in the emergence of aging-related
hypertension and suggest that the D3KO mouse may also serve as
a new animal model with which to study the mechanisms affiliated
with aging-related hypertension and cardiac remodeling.
In many tissues, a structural reorganization and enhancement of
matrix proteins including collagen, fibronectin, and proteoglycans
occur with age [54,55]. Such fibrotic changes often result in
rigidity and stiffening of the tissue with loss of functional integrity.
We found that myocardial interstitial fibrosis increased (,30%)
with age in WT animals, corresponding to expected age-related
fibrotic modifications. In comparison, in young D3KO mice
myocardial interstitial fibrosis was ,40% higher than that of age-
matched WT controls and comparable to the 2 yr old WT. In
support of the fibrosis data, IP-Western analyses of myocardial
homogenates revealed that pro- and mature collagen type-I but
not type-III or type-IV significantly increased with age in the WT
animals. In a similar fashion, young D3KO expressed significantly
elevated levels of pro- and mature collagen type-I, comparable to
that of the 2 yr old WT. A decline of the heart function with aging
and age-related cardiac fibrotic remodeling has been well
characterized [7,34]. Myocardial collagen accumulation has also
been identified as a major contributor to these aging-related
changes. Here, we identify collagen type-I as the major component
in aging-related myocyte fibrosis in WT animals, supporting
previous observations that collagen type-I is a primary collagen
isotype in the aged heart [35]. Collagen type-I expression was
significantly increased in the young D3KO and similar to levels
found in 2 yr old WT. Interestingly, an inverse relationship
between fractional shortening and myocardial collagen content
has been recently suggested to contribute to aging-related fibrotic
remodeling [56]. Additionally, although several studies have
examined the role for the D1 and/or D2 receptors on collagen
deposition following coronary artery occlusion [57] or under
conditions of experimental arthritis [58], this is the first report
highlighting a role for the D3 receptor in myocardial collagen
accumulation.
It is possible that, in addition to these measures of cardiac
remodeling, neural remodeling including changes in cardiac
neuron size, density, branching and/or fibrosis could potentially
contribute to the early onset of cardiac dysfunction observed in the
D3KO mice, and possibly also play a role in the decreased life
span of these animals. A monoamine receptor-mediated remod-
eling of cardiac neurons has been recently observed in chronic
heart disease [59], and it is conceivable that the persistent
dysfunction of the D3 receptor could also entail similar
consequences. Another intriguing hypothesis is that the increase
in cardiac fibrosis could also affect the cytoskeleton of cardiac
myocytes themselves, and that these pathological stimuli might
corroborate or induce maladaptive remodeling of cardiac neurons
[60]. Future experiments will be designed with these hypotheses in
mind, to dissociate the possible influence of altered cardiac
neurons and fibrosis in the emergence of the D3KO cardiac and
autonomic phenotype.
Considering the regulatory roles for matrix-degrading MMPs in
fibrosis, we found that the activities of the gelatinolytic MMP-2
and MMP-9 increased with age in WT cardiomyocyte homoge-
nates. Interestingly, D3KO showed comparable levels of MMP-2
activity to those of age-matched WT, yet their MMP-9 activities
were significantly elevated over all WT cohorts, nearly 8-fold
higher than age-matched WT and doubling levels observed in the
2 yr old WT. Although a correlation between modulation of D2 or
D5 receptors and MMP-9 synthesis has been previously suggested
[61,62], to date no study has reported an association between D3
receptor deficiency and MMP-9. An increase of MMP-9 levels has
been recently suggested as a potential plasma marker for cardiac
aging [63], and deletion of MMP-9 in MMP-9 null mice
attenuated the age-related decline in diastolic function [64]. Thus
the enhanced MMP-9 activity and the elevated collagen type-I
expression observed in the hearts of young D3KO suggest that
both are involved in the early establishment of the fibrotic
phenotype also present in old WT.
It is intriguing to note that young D3KO display a lack of
cardiac ventricular hypertrophy and remodeling despite develop-
Figure 8. Kaplan-Meier curve of survival for WT and D3KO
animals. Two cohorts of male animals kept were maintained and
expressed a differential survival profile. D3KO started to die prematurely
at 7 months of age, and at 15 months of age, only 67% (10/15) D3KO
mice survived while 100% (14/14) of the WT animals survived to this
time point.
doi:10.1371/journal.pone.0074116.g008
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ing increased levels of systolic and diastolic blood pressure. The
conventional notion is that hypertension stimulates compensatory
cardiac remodeling and therefore is usually associated with cardiac
hypertrophy [65,66]. However, the lack of overt differences in LV
dimensions and MCSAs between D3KO and their age-matched
WT argues that the D3KO mouse may represent a unique model
in which hypertension and interstitial fibrosis can be separated
from cardiac hypertrophy.
Conclusions
Taken together, our data provide sound evidence that
dysfunction of the dopamine D3 receptor is associated with
emergence of aging-related hypertension and changes in cardiac
function and life span. These data are consistent with the theory
that the D3KO mouse heralds a new animal model with which to
understand the role of the dopamine D3 receptor in aging heart
function, and in particular its role in cardiac remodeling associated
with hypertension.
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